Clovis leaps as AstraZeneca's AZD9291 disappoints on lung cancer

AstraZeneca may still be in front in the late-stage race to develop a targeted new drug for non-small cell lung cancer, but new data has analysts wondering if its lead over rival Clovis has shortened in the final stretch.

IBM debuts its hotly hyped 'cognitive cloud' biotech HQ in Cambridge

Cloud computing courtesy of IBM has opened up shop in the heart of the Cambridge, MA, biotech hub today, bringing with it some key industry partnerships and a familiar tech manifesto aimed at commanding a big industry audience.

Gilead banks $10B, stirring fresh buzz about a blockbuster buyout

When Gilead laid out the terms for raising $10 billion yesterday, on top of the blockbuster money it earns on HIV and its hepatitis C drugs acquired in its buyout of Pharmasset, the move immediately stirred fresh buzz about what Gilead was going to buy next, and for how much.

Takeda bets $500M on a freshly unstealthed biotech

Japanese pharma giant Takeda is promising as much as $500 million to a previously under-wraps biotech company with some early-stage drugs that could provide a more tolerable alternative to steroid treatments.

BioGaia pumps cash into orphan drug subsidiary ahead of possible spinout

BioGaia has funnelled SEK 35 million ($4 million) into the bank account of its subsidiary Infant Bacterial Therapeutics to tide the unit over while it considers how to finance clinical trials of an orphan drug. The next move could be a separate listing of the subsidiary.

Big-name backers give ReViral $21M to move RSV drug into the clinic

Edmond de Rothschild Investment Partners and OrbiMed have co-led a $21 million (€18.8 million) Series A round in ReViral, a London-based biotech that is edging a drug against respiratory syncytial virus (RSV) toward the clinic.

Clal Biotech tanks after diabetes drug in Hyperion controversy fails PhIII

After 12 months of fraud accusations, legal threats and stock price swings, Clal Biotechnology and Hyperion Therapeutics now have data from the heavily scrutinized Phase III trial of the diabetes drug at the center of their spat. The trial was a flop, Globes reports.

Shield and Faron swing for London IPOs as market heats up

Faron Pharmaceuticals and Shield Therapeutics have joined a small but growing list of biotechs to pick London over New York for their IPO. Both companies are looking to tap investors for money to push candidates through late-phase trials and on to the market.

MorphoSys to ramp up R&D expenditure to support slate of clinical trials

MorphoSys is set to ratchet up investment in R&D as it seeks to push candidates through late-phase trials and win the approvals that will allow it to evolve into a fully integrated biopharma company. The additional funds will support the startup of 5 new trials over the next 15 months.

FierceBiotech presents a half-day executive summit in London

Join me on October 12 for our special half-day biotech conference, in partnership with One Nucleus and OBN. There will be plenty of time for networking and I'll be there throughout, taking your questions as we explore new technologies and new money. Drop me a line if you have a query.

Roche backs AveXis in a $65M round for SMA gene therapy

Gene therapy biotech AveXis raised $65 million in Series D cash to advance a potential one-time treatment for the rare spinal muscular atrophy, a debilitating disease with no approved therapies.

Stymied at FDA, AcelRx claims success with PhIII pain study

Days after the FDA reiterated its demand for a new trial of AcelRx's pain drug Zalviso before it can reconsider a marketing application, the small biotech says it has garnered positive data from its late-stage study of another pain remedy in the pipeline.

Akebia soars as its anemia pill stacks up to intravenous therapy in Phase II

Akebia Therapeutics' in-development pill for anemia met its goals in a Phase II study, sending the company's share price soaring as it plots a late-stage trial.

On a crash course with Celgene? Biogen inks a $544M autoimmune drug deal

After suffering back-to-back R&D and franchise setbacks, Biogen is beefing up its pipeline with a late-stage autoimmune drug, handing over $60 million in cash and promising up to $484 million in milestones to complete the pact with Mitsubishi Tanabe.

Agenus mortgages some vaccine royalties for $115M in R&D cash

Agenus is trading away future royalties on a GlaxoSmithKline-partnered vaccine adjuvant in exchange for up to $115 million, planning to invest the proceeds in its growing pipeline of immuno-oncology treatments.

UPDATED: On the ropes, GlaxoSmithKline admits to another PhIII debacle

GlaxoSmithKline, which recruited more than 16,000 patients in a monumental postapproval effort to distinguish Breo Ellipta by improving the mortality rates of high-risk patients with COPD, says that study failed.

Tetraphase in meltdown as lead antibiotic fails PhIII

Shares of Tetraphase Pharmaceuticals just got blasted in the wake of a failed Phase III study of its lead antibiotic.

Flexion routed as lead pain drug flops in first pivotal study

Shares of Flexion Therapeutics cratered Tuesday evening after the Burlington, MA-based biotech said its lead pain treatment flopped in a pivotal Phase IIb study.

Bristol-Myers' latest PD-1 win could pave the path to earlier use

Bristol Myers-Squibb, a leader among companies at work in immuno-oncology, is pressing for wider use of its lead treatment with new data showing the injected drug could succeed as part of a first-line treatment in lung cancer.

Merck and Samsung notch their first biosimilar victory with Enbrel knockoff

Partners Merck and Samsung Bioepis recorded their first approval in a sweeping biosimilars alliance, winning a South Korean OK for their copy of Amgen's blockbuster Enbrel.